PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimer’s Disease: A Data Mining and Bioinformatics Study
The β-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) is an extensively studied therapeutic target for Alzheimer’s disease (AD), owing to its role in the production of neurotoxic amyloid beta (Aβ) peptides. However, despite numerous BACE1 inhibitors entering clinical trials, none have succe...
Main Authors: | Hannah A. Taylor, Katie J. Simmons, Eva M. Clavane, Christopher J. Trevelyan, Jane M. Brown, Lena Przemyłska, Nicole T. Watt, Laura C. Matthews, Paul J. Meakin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/9/4568 |
Similar Items
-
Role of BACE1 in Alzheimer’s synaptic function
by: Brati Das, et al.
Published: (2017-08-01) -
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
by: Miguel A. Maia, et al.
Published: (2019-03-01) -
The Emerging Roles of the β-Secretase BACE1 and the Long Non-coding RNA BACE1-AS in Human Diseases: A Focus on Neurodegenerative Diseases and Cancer
by: Arezou Sayad, et al.
Published: (2022-03-01) -
BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
by: Gerald Koelsch
Published: (2017-10-01) -
The Prognostic Value of Deleted in Colorectal Cancer (DCC) Receptor and Serum Netrin-1 in Severe Traumatic Brain Injury
by: Yuanda Zhang, et al.
Published: (2022-06-01)